free reprot icon

How Claims Data Volatility  
Is Impacting Biopharma: 
A 2025 Industry Snapshot

HeaderArt_wHeadline_1920x545_300dpi

The data volatility ripple effect 

69% of biopharma leaders reported experiencing disruptions in 
their real-world claims data in the past year. The volatility leads to 
flawed analytics, delayed timelines, and lost productivity.

A new survey sponsored by McKesson Compile™ uncovers how
volatility in real-world claims data is impacting commercialization —
and how teams are adapting.

Snapshot: Erroneous insights

The graphic below provides a preview of the analysis featured
in the report. Here, 73% of respondents claimed data issues led
to false insights. Among them, 86% were forced to reverse a
business decision. This is only a glimpse into the consequences
of data volatility.

DataVolatility_Chart_907x624_300dpi

Download the report

Get the full report to explore:

01_DataVolatility_Icon_110x110_300dpi

Where data volatility
is hitting commercial
teams the hardest
and why it often  
goes undetected 

 

02_Disruptions_Icon_110x110_300dpi

How disruptions are 
delaying decisions,
increasing rework,  
and introducing risk

 

03_BiopharmaLeaders_Icon_110x110_300dpi

What steps biopharma 
leaders are taking
to strengthen data 
reliability and vendor 
accountability

 

04_DataVendor_icon_110x110_300dpi

What to look for  
in a data vendor 
when it comes to  
data disruption

 

Fill out the form to access the complete survey findings  
and strategic recommendations.